Table 1 Baseline characteristics of 30 patients
Characteristics | All patients (n = 30) |
|---|---|
Age, years | |
Mean (range) | 56.5 (25–73) |
Sex | |
Male | 19 (63.3) |
Female | 11 (36.7) |
ECOG performance status | |
0 | 30 (100) |
1 | 0 (0) |
TNM stage at baseline | |
IIIA | 5 (16.7) |
IIIB | 13 (43.3) |
IV | 12 (40.0) |
History of hepatolithiasis | |
Yes | 1 (3.3) |
No | 29 (96.7) |
HBsAg | |
Positive | 8 (26.7) |
Negative | 22 (73.3) |
HBcAb | |
Positive | 24 (80.0) |
Negative | 6 (20.0) |
Prior systemic therapy | |
Yes | 0 (0) |
No | 30 (100) |
PD-L1 expression (IHC ≥ 1%a) | |
Positive | 14 (46.7) |
Negative | 16 (53.3) |
CA19-9 (U/mL) | |
≥37 | 21 (70.0) |
<37 | 9 (30.0) |
DDR-related gene mutation | |
Present | 21 (70.0) |
Absent | 9 (30.0) |
MSI status | |
High | 2 (6.7) |
Low | 3 (10.0) |
Stable | 25 (83.3) |
BRAF mutation | |
Yes | 3 (10.0) |
No | 27 (90.0) |
FGFR2 fusions/arrangement | |
Yes | 1 (3.3) |
No | 29 (96.7) |
IDH1 mutation | |
Yes | 1 (3.3) |
No | 29 (96.7) |
Tumor mutation burden (Muts/Mb) | |
Median (range) | 0.985 (0.08–31.82) |
